US FDA Clears IND for Cynata’s Phase 2 Clinical Trial of CYP-001 in GvHD

Link to full article Key Highlights: • US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company • Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of negotiations with […]

Cynata Advances Clinical Trial in Diabetic Foot Ulcers

Link to full article Melbourne, Australia; 21 April 2022: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to announce enrolment of initial patients in a clinical trial of CYP-006TK as a potential treatment for diabetic foot ulcers (DFU). Subjects are now being followed as planned for […]

Cynata Receives Decision to Grant a Patent in Japan

27 January 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that that a Decision to Grant a Patent has been received from the Japanese Patent Office (JPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application […]

Cynata and FUJIFILM Cellular Dynamics Execute Strategic Manufacturing Agreement

29 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce the execution of a Manufacturing Services Agreement (“MSA”) with FUJIFILM Cellular Dynamics, Inc (“FCDI”) for the manufacture and supply of Cynata’s Cymerus™ therapeutic mesenchymal stem cell (“MSC”) products derived from induced pluripotent […]

Cynata Commences DFU Clinical Trial

22 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce its clinical trial of CYP-006TK in patients with diabetic foot ulcers (DFU) has commenced and is now open for patient enrolment. The Phase I trial (protocol number CYP-DFU-P1-01) aims to recruit 30 […]

$25m spur for vital bio-med projects

Biomedical projects at the cutting edge of innovation will receive a $25m cash injection, in a boost for next-gen medicine including stem cell research, new treatments for autism and a technology that allows medicine to be taken through the skin. The $25m investment through the federal Biomedical Translation Fund will potentially benefit thousands of Australians […]

BIOSCIENCE MANAGERS: This biotech focused fund explains why it invested $15m in these 2 ASX stocks

Link to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]